Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small interfering RNA targeting YB-1
- Development stage
- Preclinical
- Lead developer
- University of British Columbia
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
Small interfering RNA targeting YB-1 is an RNA-based therapeutic approach designed to silence the expression of Y-box binding protein-1 (YB-1), a multifunctional protein that is highly expressed in various human malignancies, including glioblastoma (GBM). YB-1 acts as a key transcription and translation factor that regulates the expression of genes involved in cell proliferation, survival, and the maintenance of cancer stem cell (CSC) populations. By utilizing the RNA interference (RNAi) pathway, these siRNAs trigger the degradation of YB-1 mRNA, leading to a reduction in YB-1 protein levels. This inhibition has been shown in preclinical studies to attenuate the expression of neural stem cell markers (such as Sox-2, nestin, and musashi), reduce neurosphere growth, and induce differentiation in brain cancer stem cells, thereby potentially limiting tumor recurrence and progression.
- Other names
- YB-1 siRNAYB1 siRNAYB 1 siRNAsiRNA targeting YB-1Y-box binding protein-1 siRNA
02
Targets
YBX1 (Y-box-binding protein 1)
Beyond the preview
Go deeper on small interfering RNA targeting YB-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small interfering RNA targeting YB-1.